Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43513 | 1.00 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL43514 | 1.00 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| Gamma-Aminobutyric Acid SCHEMBL2770343 | 0.84 | KMT2A (0.41) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL29747049 | 0.81 | KMT2A (0.43) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL29747363 | 0.80 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| Hydrochloric Acid SCHEMBL9473668 | 0.80 | ALDH1A1 (0.51) | KMT2APOLBL3MBTL1SMN1; SMN2ALOX5 | |
| Hydrochloric Acid SCHEMBL9473673 | 0.80 | ALDH1A1 (0.51) | KMT2APOLBL3MBTL1SMN1; SMN2ALOX5 | |
| SCHEMBL19463110 | 0.80 | KDM4E (0.39) | POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9955771 | 0.78 | MME (0.43) | POLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL9955768 | 0.78 | MME (0.43) | POLBL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434764-B2 | Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor | UNIVERSITY OF CINCINNATI (US) | 2016-09-06 | — | — | US | claimed |
| US-20150297667-A1 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | claimed |
| US-20150299251-A1 | Skin Care Compositions and Methods Comprising Selective Agonists of Melanocortin 1 Receptor | UNIVERSITY OF CINCINNATI (US) | 2015-10-22 | — | — | US | claimed |
| EP-2925340-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-10-07 | — | — | EP | claimed |
| EP-2922565-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014081846-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2014081845-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | claimed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4545553-A2 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | ShangPharma Innovation Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025079064-A1 | INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS | PEPTICOM LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| US-11981753-B2 | Peptide compound and application thereof, and composition containing peptide compound | SHANGPHARMA INNOVATION INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2023-11-07 | — | — | US | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| EP-2922565-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | University Of Cincinnati (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081846-A2 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081845-A2 | SKIN CARE COMPOSITIONS AND METHODS COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR | UNIVERSITY OF CINCINNATI (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1121446-A1 | AMINOACYLASE AND ITS USE IN THE PRODUCTION OF D-AMINOACIDS | Chirotech Technology Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023598-A1 | AMINOACYLASE AND ITS USE IN THE PRODUCTION OF D-AMINOACIDS | CHIROTECH TECHNOLOGY LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981753-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, NPY1R, GLP1R | KMT2A 1451/4885PTPN1 400/4885POLB 4008/4885 |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | KMT2A 3979/4885PTPN1 1347/4885POLB 4665/4885 |
| US-11807660-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, SSTR3 | KMT2A 1706/4885PTPN1 1521/4885POLB 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.